XERS, CARL Stocks Hit All-Time Highs Today – Here’s What Analysts Are Saying
Xeris Biopharma (XERS) and Carlsmed (CARL) shares hit all-time highs after strong Q3 earnings. Barclays called XERS' Q3 'impressive,' raising its target to $18. XERS expects Recorlev sales to hit $1B earlier. BTIG raised CARL's target to $26, citing strong growth prospects. XERS shares up 3.8%, CARL up 22%.
How this was made
The 30-second read
Why it matters
Both firms posted stronger‑than‑expected results, prompting analyst upgrades that could fuel short‑term buying pressure.
Market read
Earnings beats and guidance lifts provide fresh catalysts for two micro‑cap stocks, likely driving near‑term upside.
What to watch
Potential regulatory or reimbursement risks for Recorlev and product adoption timelines for CARL's spine devices.
Background
The article recaps Q3 earnings releases for Xeris Biopharma (XERS) and Carlsmed (CARL), highlighting revenue beats, guidance upgrades, and analyst price‑target revisions.
Ticker impact
Q3 earnings beat estimates, 44% revenue rise and raised full‑year 2026 guidance; price target lifted to $18.
likely upward as market prices in higher revenue outlook and target raise
Earnings beat, strong demand for Recorlev, and a new price target provide fresh, material upside catalysts.
Q3 revenue up 65% to $21.6 M, beat estimates; FY2026 revenue guidance raised; BTIG and Truist lifted price targets.
likely upward as investors absorb the upgraded outlook and higher targets
New earnings data and target hikes constitute fresh, actionable information.
Market effects
Biopharma and medical‑device sectors may see modest uplift from strong Q3 results.
U.S. small‑cap biotech and med‑tech stocks could benefit from spill‑over sentiment.
Limited to investors focused on niche biotech and spine‑surgery device markets.
Counterpoint
The companies remain loss‑making; valuation may still be stretched despite earnings beat.
Key entities
- analystBarclays
Raised XERS price target to $18.
- analystBTIG
Raised CARL price target to $26.
